Information Provided By:
Fly News Breaks for January 7, 2020
PRNB
Jan 7, 2020 | 11:02 EDT
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Principia Biopharma and raised his price target to $63 from $57 as the company continues to progress is lead drug candidate, PRN1008, also known as rilzabrutinib. The analyst increased the projected chance of success for PRN1008 in ITP to 65% from 50%, increased projected U.S. ITP peak sales to $325M from $260M ex-U.S. markets not included in his valuation, and increased his projected chance of success for PRN2246/SAR442168 in MS to 35% from 20%, increasing projected peak sales to $1.05B from $850M.
News For PRNB From the Last 2 Days
There are no results for your query PRNB